I just posted the third of a four part interview with Dr. Byrd where he discusses some of the details of what we know about ibrutinib therapy so far. This is a deeper look at the complications, combinations, CAR-T and more than in my prior posts so if you are new to the subject I suggest you see the first two parts of the interview with Dr, Byrd and the interviews with Dr. Pagel at the same meeting. They all can be found at bkoffman.blogspot.com
ASH 2012 Interviews Part 3 Dr. John Byrd on Ib... - CLL Support
ASH 2012 Interviews Part 3 Dr. John Byrd on Ibrutinib
Written by
bkoffman
CLL CURE Hero
To view profiles and participate in discussions please or .
Read more about...
1 Reply
•
Hi I have watched all the videos with great hope. Enjoy your holiday in Ireland, hope the weather isn't too bad. Best wishes.
Not what you're looking for?
You may also like...
CLL Society's October 10th Virtual Global Patient Educational Forum, featuring Dr. John Byrd speaking on Clinical Trials!
CLL Society's October 10th Virtual Global Patient Educational Forum, featuring Dr. John Byrd...
Dr. Wiestner on Combos and fixed duration ibrutinib (he doesn't like the idea) and a webinar with Dr. Byrd and me
Hi everyone,
Dr. Wiestner always has a fresh perspective on CLL treatment, and my interview at ASH...
Dr. Byrd on COVID-19
Hi,
Dr. John Byrd is not only a valued member of our medical advisory board and a world leader in...
ASH 2016: Dr. Mato on real world data on ibrutinib
Hi,
This week I'm posting an interview that I had with Dr. Anthony Mato from U Penn when we talked...
Dr. John Byrd: Monitoring Vaccination Effectiveness for Preventing SARS-CoV-2 Infection & COVID-19 Syndrome in CLL
CLL Society's new Opinion Page: Dr. John Byrd on Monitoring Vaccination Effectiveness for...